Exogenous Metabolic Modulators Improve Response to Carboplatin in Triple-Negative Breast Cancer
Cells · 09.05.2024 · 13 (10) · 806
DOI: 10.3390/cells13100806 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 09.05.2024. Verfasst von Alyssa N Ho und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Hauptthemen laut MEDLINE: Carboplatin, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Breast Cancer Research Foundation, NIDDK NIH HHS.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) lacks targeted therapies, leaving cytotoxic chemotherapy as the current standard treatment. However, chemotherapy resistance remains a major clinical challenge. Increased insulin-like growth factor 1 signaling can potently blunt chemotherapy response, and lysosomal processes including the nutrient scavenging pathway autophagy can enable cancer cells to evade chemotherapy-mediated cell death. Thus, we tested whether inhibition of insulin receptor/insulin-like growth factor 1 receptor with the drug BMS-754807 and/or lysosomal disruption with hydroxychloroquine (HCQ) could sensitize TNBC cells to the chemotherapy drug carboplatin. Using in vitro studies in multiple TNBC cell lines, in concert with in vivo studies employing a murine syngeneic orthotopic transplant model of TNBC, we show that BMS-754807 and HCQ each sensitized TNBC cells and tumors to carboplatin and reveal that exogenous metabolic modulators may work synergistically with carboplatin as indicated by Bliss analysis. Additionally, we demonstrate the lack of overt in vivo toxicity with our combination regimens and, therefore, propose that metabolic targeting of TNBC may be a safe and effective strategy to increase sensitivity to chemotherapy. Thus, we conclude that the use of exogenous metabolic modulators, such as BMS-754807 or HCQ, in combination with chemotherapy warrants additional study as a strategy to improve therapeutic responses in women with TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Nutrition Research Institute, University of North Carolina at Chapel Hill, Kannapolis, NC 28081, USA.
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
ORCID-Profile: Alyssa N Ho, Violet A Kiesel, Scott P Connelly, Elaine M Glenny, Michael Francis Coleman
Förderung
- NCI NIH HHS
- Breast Cancer Research Foundation
- NIDDK NIH HHS
Zitieren
APA
Ho, A. N., Kiesel, V. A., Gates, C. E., Brosnan, B. H., Connelly, S. P., Glenny, E. M., Cozzo, A. J., Hursting, S. D., & Coleman, M. F. (2024). Exogenous Metabolic Modulators Improve Response to Carboplatin in Triple-Negative Breast Cancer. Cells, 13(10), 806. https://doi.org/10.3390/cells13100806
Vancouver
Ho AN, Kiesel VA, Gates CE, Brosnan BH, Connelly SP, Glenny EM, et al. Exogenous Metabolic Modulators Improve Response to Carboplatin in Triple-Negative Breast Cancer. Cells. 2024;13(10):806. doi:10.3390/cells13100806
BibTeX
@article{Ho2024,
author = {Ho, Alyssa N and Kiesel, Violet A and Gates, Claire E and Brosnan, Bennett H and Connelly, Scott P and Glenny, Elaine M and Cozzo, Alyssa J and Hursting, Stephen D and Coleman, Michael Francis},
title = {Exogenous Metabolic Modulators Improve Response to Carboplatin in Triple-Negative Breast Cancer},
journal = {Cells},
year = {2024},
volume = {13},
number = {10},
pages = {806},
doi = {10.3390/cells13100806}
}
EUVIMED